2. Search Result
Search Result
Pathways Recommended: Anti-infection
Results for "

Clostridium difficile infection

" in MedChemExpress (MCE) Product Catalog:

15

Inhibitors & Agonists

1

Inhibitory Antibodies

4

Natural
Products

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-17580
    Fidaxomicin
    5+ Cited Publications

    OPT-80; PAR-101

    		 DNA/RNA Synthesis Bacterial Apoptosis Antibiotic Infection
    Fidaxomicin (OPT-80), a macrocyclic antibiotic, is an orally active and potent RNA polymerase inhibitor. Fidaxomicin has a narrow spectrum of antibacterial activity and a good anti-Clostridium difficile activity (MIC90=0.12 μg/mL). Fidaxomicin can be used for Clostridium difficile infection (CDI) research .
    Fidaxomicin
  • HY-107830
    Methyl cholate

    		Endogenous Metabolite Collagen Infection Metabolic Disease
    Methyl cholate is a bile acid analog and a specific inhibitor of TcdB toxin from Clostridioides difficile. Methyl cholate exerts a stronger selective inhibitory effect on TcdB than on TcdA. Methyl cholate induces conformational stabilization by binding to a unique site of TcdB, thereby blocking the binding of the toxin to host receptors and its self-processing process. Methyl cholate effectively protects human fibroblasts from TcdB-induced cytopathic effects. Methyl cholate exhibits dose-dependent anti-hepatic fibrosis activity in both cellular and zebrafish models, and significantly reduces the expression levels of α-SMA and COL-I. Methyl cholate is suitable for in-depth research in the fields of Clostridioides difficile infection and hepatic fibrosis .
    Methyl cholate
  • HY-P9929
    Bezlotoxumab
    1 Publications Verification

    BLA761046; MBL-CDB1; MDX-1388

    		 Bacterial Infection
    Bezlotoxumab (BLA761046; MBL-CDB1; MDX-1388) is a fully humanized IgG1/kappa monoclonal antibody directed against Clostridium difficile toxin B. Bezlotoxumab mediates the early reconstitution of gut microbiota to reduce the risk of recurrent Clostridium difficile infection (CDI). Bezlotoxumab can be used for the study of recurrent Clostridium difficile infection prevention .
    Bezlotoxumab
  • HY-128357
    Ibezapolstat
    4 Publications Verification

    ACX-362E; GLS-362E

    		 Bacterial DNA/RNA Synthesis Infection
    Ibezapolstat (ACX-362E) is a first-in-class, orally active DNA polymerase IIIC (pol IIIC) inhibitor, with a Ki of 0.325 μM for the DNA pol IIIC from C. difficile. Ibezapolstat is developed for the research of C. difficile infection(CDI) .
    Ibezapolstat
  • HY-103249
    Reutericyclin

    Reutericycline

    		 Bacterial Infection Metabolic Disease
    Reutericyclin (Reutericycline) is an orally active antibacterial and anti-obesity agent that selectively inhibits Gram-positive bacteria. By selectively dissipating transmembrane potential, Reutericyclin exerts non-lytic bactericidal or bacteriostatic activity against pathogens such as Clostridium difficile and Staphylococcus aureus, and rapidly kills vegetative cells and spores of Clostridium difficile. Reutericyclin possesses favorable properties including resistance to enzymatic hydrolysis, iron-chelating function, and poor absorption by colonic epithelium. Reutericyclin not only eradicates staphylococcal biofilms and inhibits drug-resistant strains, but also counteracts Risperidone (HY-11018)-induced weight gain by inducing changes in gut microbiota composition and restoring energy utilization efficiency. Reutericyclin can be used in research related to Clostridium difficile infection, Risperidone-induced weight gain, and staphylococcal superficial skin infections .
    Reutericyclin
  • HY-105099
    Rifalazil

    KRM-1648; ABI-1648

    		 Antibiotic DNA/RNA Synthesis Bacterial Infection Inflammation/Immunology
    Rifalazil (KRM-1648; ABI-1648), a rifamycin derivative, inhibits the bacterial DNA-dependent RNA polymerase and kills bacterial cells by blocking off the β-subunit in RNA polymerase . Rifalazil (KRM-1648; ABI-1648) is an antibiotic, exhibits high potency against mycobacteria, gram-positive bacteria, Helicobacter pylori, C. pneumoniae and C. trachomatis with MIC values from 0.00025 to 0.0025 μg/ml . Rifalazil (KRM-1648; ABI-1648) has the potential for the treatment of Chlamydia infection, Clostridium difficile associated diarrhea (CDAD), and tuberculosis (TB) .
    Rifalazil
  • HY-18324
    CRS3123
    1 Publications Verification

    REP-3123

    		 Antibiotic Inflammation/Immunology
    CRS3123 is a potent and orally active narrow-spectrum antibiotic. CRS3123 inhibits bacterial methionyl-tRNA synthetase. CRS3123 has potent activity against Clostridium difficile (C. difficile) and aerobic Gram-positive bacteria but little activity against Gram-negative bacteria, including anaerobes. CRS3123 has the potential for the research of C. difficile infections .
    CRS3123
  • HY-B1127
    Betamipron

    N-Benzoyl-β-alanine

    		 Antibiotic Bacterial Infection Endocrinology
    Betamipron (N-benzoyl-β-alanine) is a carbapenem β-lactam antibiotic with antibacterial activity against most Gram-positive and Gram-negative aerobic and anaerobic bacteria. Betamipron can target and inhibit renal organic anion transporters, alleviate renal injury caused by Cisplatin (HY-17394), without interfering with the biological activity of cisplatin. Betamipron is often used in combination with panipenem, which can attenuate the renal effects induced by panipenem and slightly promote the proliferation of Clostridium difficile in the cecum. Betamipron can be used in studies related to renal injury and bacterial infection .
    Betamipron
  • HY-17580R
    Fidaxomicin (Standard)

    OPT-80 (Standard); PAR-101 (Standard)

    		 Reference Standards DNA/RNA Synthesis Bacterial Apoptosis Antibiotic Infection
    Fidaxomicin (Standard) is the analytical standard of Fidaxomicin. This product is intended for research and analytical applications. Fidaxomicin (OPT-80), a macrocyclic antibiotic, is an orally active and potent RNA polymerase inhibitor. Fidaxomicin has a narrow spectrum of antibacterial activity and a good anti-Clostridium difficile activity (MIC90=0.12 μg/mL). Fidaxomicin can be used for Clostridium difficile infection (CDI) research .
    Fidaxomicin (Standard)
  • HY-128357A
    Ibezapolstat hydrochloride

    ACX-362E hydrochloride; GLS-362E hydrochloride

    		 Bacterial DNA/RNA Synthesis Infection
    Ibezapolstat hydrochloride is a first-in-class, orally active DNA polymerase IIIC (pol IIIC) inhibitor, with a Ki of 0.325 μM for the DNA pol IIIC from C. difficile. Ibezapolstat hydrochloride is developed for the research of C. difficile infection(CDI) .
    Ibezapolstat hydrochloride
  • HY-B1127R
    Betamipron (Standard)

    N-Benzoyl-β-alanine (Standard)

    		 Reference Standards Bacterial Antibiotic Infection Endocrinology
    Betamipron (Standard) is the analytical standard of Betamipron (HY-B1127). This product is intended for research and analytical applications. Betamipron (N-benzoyl-β-alanine) is a carbapenem β-lactam antibiotic with antibacterial activity against most Gram-positive and Gram-negative aerobic and anaerobic bacteria. Betamipron can target and inhibit renal organic anion transporters, alleviate renal injury caused by Cisplatin (HY-17394), without interfering with the biological activity of cisplatin. Betamipron is often used in combination with panipenem, which can attenuate the renal effects induced by panipenem and slightly promote the proliferation of Clostridium difficile in the cecum. Betamipron can be used in studies related to renal injury and bacterial infection .
    Betamipron (Standard)
  • HY-105099R
    Rifalazil (Standard)

    KRM-1648 (Standard); ABI-1648 (Standard)

    		 Antibiotic Reference Standards DNA/RNA Synthesis Bacterial Infection Inflammation/Immunology
    Rifalazil (Standard) is the analytical standard of Rifalazil. This product is intended for research and analytical applications. Rifalazil (KRM-1648; ABI-1648), a rifamycin derivative, inhibits the bacterial DNA-dependent RNA polymerase and kills bacterial cells by blocking off the β-subunit in RNA polymerase[1]. Rifalazil (KRM-1648; ABI-1648) is an antibiotic, exhibits high potency against mycobacteria, gram-positive bacteria, Helicobacter pylori, C. pneumoniae and C. trachomatis with MIC values from 0.00025 to 0.0025 μg/ml[3]. Rifalazil (KRM-1648; ABI-1648) has the potential for the treatment of Chlamydia infection, Clostridium difficile associated diarrhea (CDAD), and tuberculosis (TB)[2].
    Rifalazil (Standard)
  • HY-138135
    OP-1118

    Fidaxomicin metabolite OP-1118

    		 NF-κB ERK Apoptosis Bacterial Infection
    OP-1118 (Fidaxomicin metabolite OP-1118) is an orally active dual inhibitor of NF-κB and ERK1/2, with low systemic plasma exposure, no accumulation, and primary excretion via feces. By inhibiting the phosphorylation of NF-κB and ERK1/2 and reducing the expression of pro-inflammatory cytokines, OP-1118 exerts significant anti-inflammatory, cytoprotective, anti-apoptotic and antibacterial activities. In Clostridium difficile infection models, OP-1118 effectively blocks toxin-mediated intestinal inflammation, cell rounding, histological damage and apoptosis, and its protective effect can be reversed by PMA (HY-18739) .
    OP-1118
  • HY-182464
    DABMA

    		Potassium Channel Infection Others
    DABMA is a TMEM175 channel activator with a human EC50 of 17.9 μM. DABMA directly increases TMEM175 channel current via interaction with intracellular, transmembrane, or endosomal lumen-associated domains, and does not alter TMEM175 mRNA or protein levels. DABMA delays endolysosomal substrate degradation, modulates endolysosomal trafficking, increases acidic organelle accumulation, induces cholesterol accumulation and altered late endosome morphology. DABMA can be used for the research of coronavirus disease, Clostridium difficile infection, Pseudomonas aeruginosa infection, rabies, and influenza virus infection .
    DABMA
  • HY-116880
    DS-2969b

    		Bacterial DNA/RNA Synthesis Infection
    DS-2969b is an orally active GyrB inhibitor with antibacterial activity. DS-2969b is is active against Clostridium difficile infection (MIC90: 0.06 μg/mL), which is 2-, 16-, and 32-fold lower than those of Fidaxomicin (HY-17580), Metronidazole (HY-B0318), and Vancomycin (HY-B0671), respectively. DS-2969b inhibits the supercoiling activity of C. difficile DNA gyrase. DS-2969b also exhibits activity against other Gram-positive anaerobes, including strict and facultative anaerobes. DS-2969b is safe and well tolerated in preclinical toxicology studies .
    DS-2969b

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: